An experimental malaria vaccine has been found to protect a small number of healthy people from infection for more than one year after immunisation says a study. The vaccine known as the PfSPZ Vaccine was developed and produced by US-based biotechnology firm Sanaria. It is now clear that administering the PfSPZ Vaccine intravenously confers long-term sterile protection in a small number of participants which has not been achieved with other current vaccine approaches said principal investigator of the trial Robert Seder from National Institute of Allergy and Infectious Diseases (NIAID) part of the US National Institutes of Health. NIAID researchers